CN

CN
News
News
News
Always Share with You
Every Bit of Our Progress
Home > News > Details
MicroPort® CardioFlow Receives Approval for VitaFlow Liberty® in Russia
2023-10-13
Back

Shanghai, China - MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK) recently announced that following Alwide® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty® ") has received marketing approval from the Russian State Food and Drug Regulatory Agency (RZN).

 

VitaFlow Liberty® is the world’s only electric retrievable transcatheter aortic valve system, offering outstanding stability during procedure and hemodynamics post-procedure that will improve the quality of life for patients with aortic valve disease. It inherits the advantages of the VitaFlow® in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and a high double-layer PET skirt design. This design offers robust radial force, improved coaxiality during deployment, and effectively reduces the incidence of perivalvular leakage post-procedure. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

 

Previously, MicroPort® CardioFlow’s two generations of TAVI products, VitaFlow® and VitaFlow Liberty®, have fully covered more than 500 core hospitals in China and more than 80 core hospitals in overseas countries since their listing. The approval of VitaFlow Liberty® in Russia marked another important milestone for MicroPort® CardioFlow in the internationalization development , following Argentina, Colombia and Thailand. In the future, MicroPort® CardioFlow will continue to develop innovative technologies and launch more internationally competitive products to provide high-quality, universal total solutions for structural heart disease to more patients around the world.

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.


CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

×
TOP

©Copyright 1998-2023, MicroPort CardioFlow Medtech Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备2023023560号 沪公网安备 31011502014876号

互联网药品信息服务资格证书编号:(沪)-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.